Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease-Reference-Cited by-全球学者库

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease

Published:2019-02-22 Issue:6 Volume:69 Page:2414-2426
ISSN:0270-9139
Container-title:Hepatology
language:en
Short-container-title:Hepatology

Author:

Yan Jinhua¹,Yao Bin¹,Kuang Hongyu²,Yang Xubin¹,Huang Qin³,Hong Tianpei⁴,Li Yushu⁵,Dou Jingtao⁶,Yang Wenying⁷,Qin Guijun⁸,Yuan Huijuan⁹,Xiao Xinhua¹⁰,Luo Sihui¹,Shan Zhongyan⁵,Deng Hongrong¹,Tan Ying¹,Xu Fen¹,Xu Wen¹,Zeng Longyi¹,Kang Zhuang¹,Weng Jianping¹^ORCID

Affiliation:

1. The Third Affiliated Hospital of Sun Yat-sen University, Guangdong Provincial Key Laboratory of Diabetology; Guangzhou China

2. The First Affiliated Hospital of Harbin Medical University; Harbin China

3. Changhai Hospital; Shanghai China

4. Peking University Third Hospital; Beijing China

5. The First Hospital of China Medical University; Shenyang China

6. Chinese PLA General Hospital; Beijing China

7. CHINA-JAPAN Friendship Hospital; Beijing China

8. The First Affiliated Hospital of Zhengzhou University; Zhengzhou China

9. Henan Provincial Peoples Hospital; Zhengzhou China

10. Peking Union Medical College Hospital; Beijing China

Funder

Novo Nordisk

National Natural Science Foundation of China

Pearl River S and T Nova Program of Guangzhou

Guangdong High-Level Talents Special Support Program

Publisher

Wiley

Subject

Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/hep.30320/fullpdf

Reference34 articles.

1. The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases;Chalasani;Hepatology,2018

2. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease;European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO);J Hepatol,2016

3. Epidemiology of non-alcoholic fatty liver disease in China;Fan;J Hepatol,2009

4. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes;Younossi;Hepatology,2016

5. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis;Diehl;N Engl J Med,2017

Cited by 162 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Integrated traditional Chinese and Western medicine in the prevention and treatment of non-alcoholic fatty liver disease: future directions and strategies;Chinese Medicine;2024-02-03

2. Liraglutide Improves Nonalcoholic Fatty Liver Disease in Diabetic Mice by Activating Autophagy Through AMPK/mTOR Signaling Pathway;Diabetes, Metabolic Syndrome and Obesity;2024-02

3. Endpoints in NASH Clinical Trials: Are We Blind in One Eye?;Metabolites;2024-01-08

4. Review article: Pharmacologic management of obesity ‐ updates on approved medications, indications and risks;Alimentary Pharmacology & Therapeutics;2024-01-02

5. Extensive therapeutic effects, underlying molecular mechanisms and disease treatment prediction of Metformin: a systematic review;Translational Research;2024-01